Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14237015 | 0.89 | MAPT (0.41) | MEN1KMT2AHTR6LMNAHTT | |
| SCHEMBL14237108 | 0.89 | MEN1 (0.53) | MEN1KMT2ATSHRLMNAHTT | |
| Hydrochloric Acid SCHEMBL1627340 | 0.88 | MAPT (0.40) | MEN1KMT2AHTR6LMNAHTT | |
| Hydrochloric Acid SCHEMBL1625987 | 0.88 | MEN1 (0.53) | MEN1KMT2ATSHRLMNAHTT | |
| SCHEMBL14237117 | 0.86 | HTR6 (0.40) | MEN1KMT2AHTR6LMNAMAPT | |
| SCHEMBL14236989 | 0.84 | MCOLN2 (0.41) | MEN1KMT2AHTR6LMNA | |
| SCHEMBL14237009 | 0.84 | HTR6 (0.37) | MEN1KMT2AHTR6LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1626825 | 0.83 | MCOLN2 (0.40) | MEN1KMT2AHTR6TSHRLMNA | |
| Hydrochloric Acid SCHEMBL1626589 | 0.83 | HTR6 (0.36) | MEN1KMT2AHTR6LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1626777 | 0.81 | GAA (0.38) | MEN1KMT2AHTR6TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831195-B1 | 5-HT7 RECEPTOR ANTAGONISTS | ESTEVE LABOR DR (ES) | 2012-12-19 | — | — | EP | claimed |
| US-8822233-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | GIRI BRIJ PAL (US) | 2014-09-02 | — | — | US | disclosed |
| EP-1831195-B1 | 5-HT7 RECEPTOR ANTAGONISTS | ESTEVE LABOR DR (ES) | 2012-12-19 | — | — | EP | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-7345057-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-18 | — | — | US | disclosed |
| US-20060142332-A1 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | HTR7, HTR1A, HTR5A | MEN1 1107/4885KMT2A 2422/4885HTR6 7/4885 |
| US-20060142332-A1 | 5-HT7 receptor antagonists | HTR7, HTR1A, HTR5A | MEN1 1322/4885KMT2A 2373/4885HTR6 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.